Search for a trial

Seizure detection and automatic magnet mode performance study

The primary study objective is to evaluate the Model 106 VNS Therapy® System cardiac-based seizure detection and Automated Magnet Mode (AMM) stimulation in epilepsy patients. These two new features will be evaluated using continuous observational…

CONNECTION PLUS: An Open-Label Extension of the CONNECTION Protocol (DIM14) Evaluating Oral Dimebon in Patients with Alzheimer*s Disease

To evaluate the long-term safety and tolerability of Dimebon in AD patients who have successfully completed 26 weeks of blinded treatment in the CONNECTION Study (DIM14) (hereafter referred to as *CONNECTION*).

Effects of robot-assisted treadmill training in combination with resistance exercise on locomotor performance and quality of life as well as cardiovascular and neuromuscular properties in patients after stroke and individuals with spinal cord injury.

The primary objective of the SCI and to investigate its effectiveness on locomotor performance, participation and quality of life. The proposed study further aims to assess the time course of effects, not only during the training period, but also…

T-REEX: Phase locked TRanscranial Electrical EXcitation

The aim of this study is to demonstrate that accurate brain stimulation is possible in anatomical location and timing.

Metabolic MRI in brain cancer and epilepsy

Develop a fast metabolic MRI protocol, based on DMI and 31P-MRSI at ultra-high field MRI, to investigate the Warburg effect and phospholipid metabolism in glioblastoma and to asses metabolic disruption in epilepsy.

*EPILEPSY AND ANXIETY: TARGETING A VICIOUS CYCLE. Effectiveness of EMDR in targeting epilepsy-related anxiety, quality of life and subjective cognitive functioning*

To test the hypotheses that EMDR therapy will significantly (1) reduce anxiety in persons with epilepsy-related anxiety symptoms, from pre-treatment to post-treatment, (2) reduce seizure frequency and severity and will (3) improve quality of life…

Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Two Year Study to Evaluate the Effect of Subcutaneous RO4909832 on Cognition and Function in Prodromal Alzheimer's Disease with Option for up to an Additional Two Years of Treatment and up to Three Years of an Open-Label Extension with Active Study Treatment

To assess short-term and long-term safety and tolerability of gantenerumab (RO4909832) given at doses up to 1200mg subcutaneous (SC) every 4 weeks (Q4W).Secondary Objective of the Open-label extension:- To evaluate of the effect of 1200 mg…